Glyn Parkin

Professional Overview

Glyn Parkin is a seasoned pharmaceutical executive with over 20 years of experience in the diabetes and metabolic disorders space. As the Chairman of the Board at DiogenX, he leverages his deep industry expertise and strategic leadership to guide the company's growth and innovation initiatives.

Experience Summary

Current Role

As the Chairman of the Board at DiogenX since November 2020, Glyn is responsible for providing strategic direction, overseeing governance, and ensuring the company's long-term success. Under his leadership, DiogenX has strengthened its position as a leading innovator in the diabetes and metabolic disorders space, driving the development of groundbreaking therapies.

Career Progression

Prior to his current role, Glyn served as the Non-executive Chair of the Board of Directors at Reframe from 2017 to 2021. He also held the position of Chief Executive Officer at ACTIMED THERAPEUTICS from 2017 to 2019, where he led the company's strategic and operational initiatives.

Earlier in his career, Glyn held various senior-level positions at Boehringer Ingelheim, including SVP and Global Head of Therapeutic Area Diabetes and Metabolic Disorders, as well as Head of Corporate Marketing, Diabetes/Metabolism. He also served as the Managing Director UK and SVP of International Operations at The Medicines Company.

Academic Background

Glyn holds a degree in Pharmaceutical Sciences, demonstrating his strong academic foundation in the field.

Areas of Expertise

Glyn's expertise spans the areas of strategic leadership, pharmaceutical marketing, R&D, and global operations. He has a deep understanding of the diabetes and metabolic disorders industry, having led the development and commercialization of innovative therapies. Glyn's strong background in corporate governance and board-level decision-making has been instrumental in driving the success of the organizations he has been associated with.

Professional Impact

Under Glyn's leadership, DiogenX has achieved significant milestones, including the successful launch of novel diabetes treatments and the expansion of the company's global footprint. He has also been recognized for his contributions to the industry, serving on various advisory boards and speaking at prominent pharmaceutical conferences.

Conclusion

Glyn Parkin's extensive experience and proven track record in the pharmaceutical industry make him a valuable asset to DiogenX. As the Chairman of the Board, he continues to drive the company's growth and innovation, positioning it as a leader in the diabetes and metabolic disorders space.